NASDAQ : ZURA
Zura Bio Limited — Financial statements
Healthcare · Biotechnology · United States
Last price 4.04 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 389.15M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2022 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 36.10M | 33.16M | 30.79M | 18.64M | 3.79M | 1.91M |
| Research & Development | 65.90M | 42.08M | 24.40M | 44.00M | 25.84M | 45.00M |
| Operating Expenses | 102.00M | 75.25M | 55.19M | 62.64M | 29.63M | 46.91M |
| Operating Income | -102.00M | -75.25M | -55.19M | -62.64M | -29.63M | -46.91M |
| Interest & Investment Income | 6.27M | 6.34M | 8.00M | 3.58M | 8.73K | |
| Other Non Operating Income (Expenses) | 901.00K | 260.00K | -5.21M | 741.00K | -195.27K | |
| EBT Excluding Unusual Items | -94.83M | -68.65M | -52.40M | -58.32M | -29.82M | -46.91M |
| Other Unusual Items | -2.24M | |||||
| Pretax Income | -94.83M | -68.65M | -52.40M | -60.56M | -29.82M | -46.91M |
| Earnings From Continuing Operations | -93.53M | -68.65M | -52.40M | -60.56M | -29.82M | -46.91M |
| Minority Interest in Earnings | 203.00K | 1.74M | ||||
| Net Income | -93.53M | -68.65M | -52.40M | -60.36M | -28.08M | -46.91M |
| Preferred Dividends & Other Adjustments | 28.71M | 30.70M | -7.02M | 8.88M | 7.26M | |
| Net Income to Common | -122.23M | -99.35M | -45.39M | -69.24M | -35.33M | -46.91M |
| Shares Outstanding (Basic) | 115.43M | 94.16M | 75.07M | 33.06M | 228.15K | |
| Shares Outstanding (Diluted) | 115.43M | 94.16M | 75.07M | 33.06M | 228.15K | |
| EPS (Basic) | -1.06 | -1.06 | -0.60 | -2.09 | -154.88 | |
| EPS (Diluted) | -1.06 | -1.06 | -0.60 | -2.09 | -154.88 | |
| Free Cash Flow | -81.69M | -64.93M | -28.15M | -15.05M | -1.31M | -1.68M |
| Free Cash Flow Per Share | -0.71 | -0.69 | -0.38 | -0.46 | -5.75 | |
| EBITDA | -101.94M | -75.20M | -55.18M | |||
| D&A For EBITDA | 67.00K | 49.00K | 9.00K | |||
| EBIT | -102.00M | -75.25M | -55.19M | -62.64M | -29.63M | -46.91M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2022 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 187.65M | 109.41M | 176.50M | 99.81M | 1.57M | 4.72M |
| Cash & Short-Term Investments | 187.65M | 109.41M | 176.50M | 99.81M | 1.57M | 4.72M |
| Prepaid Expenses | 3.94M | 2.90M | 2.25M | 1.04M | 209.00K | |
| Total Current Assets | 191.59M | 112.31M | 178.74M | 100.84M | 1.78M | 4.72M |
| Property, Plant & Equipment | 153.00K | 126.00K | 91.00K | |||
| Long-Term Deferred Charges | 3.49M | |||||
| Other Long-Term Assets | 2.88M | 1.51M | 698.00K | |||
| Total Assets | 194.63M | 113.95M | 179.53M | 100.84M | 5.26M | 4.72M |
| Accounts Payable | 758.00K | 1.28M | 733.00K | 2.75M | 2.01M | 7.00K |
| Accrued Expenses | 14.93M | 11.13M | 9.28M | 7.55M | 822.00K | |
| Short-Term Debt | 7.76M | |||||
| Other Current Liabilities | 9.50M | 10.00M | 4.23M | 32.00K | ||
| Total Current Liabilities | 16.97M | 12.41M | 19.51M | 20.30M | 14.82M | 39.00K |
| Other Long-Term Liabilities | 990.00K | |||||
| Total Liabilities | 16.97M | 12.41M | 19.51M | 21.29M | 14.82M | 39.00K |
| Common Stock | 10.00K | 7.00K | 7.00K | 4.00K | ||
| Additional Paid-In Capital | 478.55M | 326.08M | 302.70M | 162.82M | ||
| Retained Earnings | -300.90M | -224.55M | -155.90M | -103.49M | -32.06M | -7.82M |
| Total Common Equity | 177.66M | 101.54M | 146.81M | 59.33M | -32.06M | -7.82M |
| Minority Interest | 13.20M | 20.22M | 10.00M | |||
| Shareholders' Equity | 177.66M | 101.54M | 160.02M | 79.55M | -9.56M | 4.68M |
| Total Liabilities & Equity | 194.63M | 113.95M | 179.53M | 100.84M | 5.26M | 4.72M |
| Total Debt | 7.76M | |||||
| Net Cash (Debt) | 187.65M | 109.41M | 176.50M | 99.81M | -6.19M | 4.72M |
| Net Cash Per Share | 1.63 | 1.16 | 2.35 | 3.02 | -27.13 | |
| Filing Date Shares Outstanding | 96.33M | 94.88M | 68.37M | 43.59M | 43.09M | 17.25M |
| Total Common Shares Outstanding | 96.31M | 73.68M | 65.30M | 43.59M | 383.48K | 17.25M |
| Working Capital | 174.62M | 99.90M | 159.23M | 80.54M | -13.04M | 4.68M |
| Book Value Per Share | 1.84 | 1.38 | 2.25 | 1.36 | -83.59 | -0.45 |
| Tangible Book Value | 177.66M | 101.54M | 146.81M | 59.33M | -32.06M | -7.82M |
| Tangible Book Value Per Share | 1.84 | 1.38 | 2.25 | 1.36 | -83.59 | -0.45 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2022 | |
|---|---|---|---|---|---|---|
| Net Income | -93.53M | -68.65M | -52.40M | -60.36M | -28.08M | -46.91M |
| Depreciation & Amortization | 67.00K | 49.00K | 9.00K | |||
| Asset Writedown & Restructuring Costs | 27.38M | 23.88M | ||||
| Stock-Based Compensation | 17.36M | 12.33M | 16.80M | 9.65M | 364.36K | |
| Other Operating Activities | -7.51M | -4.91M | 5.21M | 3.15M | -1.34M | 45.00M |
| Change in Accounts Payable | 1.41M | -2.16M | 4.21M | 5.94M | 4.09M | 234.00K |
| Change in Other Net Operating Assets | 598.00K | -1.47M | -1.91M | -828.00K | -228.00K | |
| Operating Cash Flow | -81.60M | -64.81M | -28.08M | -15.05M | -1.31M | -1.68M |
| Capital Expenditures | -90.00K | -113.00K | -75.00K | |||
| Sale (Purchase) of Intangibles | -5.00M | -8.00M | -13.09M | -30.00M | ||
| Investing Cash Flow | -90.00K | -113.00K | -5.08M | -8.00M | -13.09M | -30.00M |
| Total Debt Issued | 8.29M | |||||
| Short-Term Debt Repaid | -10.00M | |||||
| Total Debt Repaid | -10.00M | |||||
| Net Debt Issued (Repaid) | -10.00M | 8.29M | ||||
| Issuance of Common Stock | 135.76M | 5.40M | 68.16M | 120.61M | ||
| Repurchase of Common Stock | -138.00K | -41.00K | -318.00K | |||
| Other Financing Activities | -5.30M | -7.53M | 42.00M | 10.69M | -3.09M | |
| Financing Cash Flow | 130.32M | -2.16M | 109.84M | 121.29M | 16.11M | 60.00M |
| Net Cash Flow | 48.63M | -67.09M | 76.69M | 98.24M | 1.71M | 28.32M |
| Free Cash Flow | -81.69M | -64.93M | -28.15M | -15.05M | -1.31M | -1.68M |
| Free Cash Flow Per Share | -0.71 | -0.69 | -0.38 | -0.46 | -5.75 | |
| Levered Free Cash Flow | -55.60M | -42.52M | -24.76M | -25.08M | ||
| Unlevered Free Cash Flow | -55.60M | -42.52M | -24.76M | -25.08M | ||
| Change in Working Capital | 2.01M | -3.63M | 2.31M | 5.12M | 3.86M | 234.00K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2022 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 382.89M | 340.72M | 163.23M | 203.58M | 176.12M | 170.95M |
| Enterprise Value | 195.24M | 211.91M | -7.21M | 122.14M | 185.57M | |
| Last Close Price | 4.04 | 5.24 | 2.50 | 4.67 | 10.21 | 9.91 |
| PB Ratio | 2.19 | 3.36 | 1.02 | 2.56 | -18.43 | 36.52 |
| P/TBV Ratio | 2.18 | 3.36 | 1.11 | 3.43 | ||
| Debt / Equity Ratio | -0.81 | |||||
| Net Debt / Equity Ratio | -1.06 | -1.08 | -1.10 | -1.25 | -0.65 | -1.01 |
| Net Debt / EBITDA Ratio | 1.84 | 1.46 | 3.20 | |||
| Net Debt / FCF Ratio | 2.30 | 1.69 | 6.27 | 6.63 | -4.72 | 2.81 |
| Quick Ratio | 11.06 | 8.82 | 9.04 | 4.92 | 0.11 | 121.03 |
| Current Ratio | 11.29 | 9.05 | 9.16 | 4.97 | 0.12 | 121.03 |
| Return on Equity (ROE) | -63.17% | -52.49% | -43.75% | -173.05% | ||
| Return on Assets (ROA) | -37.66% | -32.05% | -24.61% | -73.79% | ||
| Return on Capital Employed (ROCE) | -57.40% | -74.10% | -34.50% | -77.80% | 310.10% | -1,002.20% |
| Earnings Yield | -26.64% | -20.15% | -32.10% | -29.65% | -15.94% | -27.44% |
| FCF Yield | -21.10% | -19.06% | -17.25% | -7.40% | -0.74% | -0.98% |
| Buyback Yield / Dilution | -23.86% | -25.43% | -127.05% | -14,392.36% |